Navigation Links
New target for cancer therapy identified, preclinical study shows
Date:1/31/2012

this relationship," said study lead investigator, Benoit J. Van den Eynde, M.D., Ph.D., Brussels Branch Director at LICR.

The group studied a series of 104 human tumor lines of different types to confirm the activity of TDO in tumor cells. They learned that 20 tumors expressed TDO only, 17 others expressed IDO1 only and 16 expressed both. The findings suggest that TDO and IDO1 enzymes represent complementary cancer immunotherapy targets, which if blocked could potentially impact 51% of all tumors.

Demonstrating TDO Expression and Its Role in Thwarting Immune Attack

Using a validated mouse tumor model, researchers established that TDO expression caused tumor cells to resist immune rejection. They first vaccinated the mice with an antigen that caused them to reject the tumor. Then they injected TDO-expressing tumor cells into the immunized mice. Researchers found that immunized mice no longer rejected the TDO-expressing tumors. This demonstrated that the presence of TDO prevented the immune system from attacking tumors.

In collaboration with scientists from the University of Namur (Belgium), the team then developed an active compound to inhibit TDO enzymatic activity. "Our study showed quite beautifully that the TDO inhibitor restored the ability of mice to reject tumors despite the presence of TDO in tumor cells," said Dr. Van den Eynde.

Research recently published in the October 6, 2011 issue of Nature (Opitz, C.A. et al.) validates today's study results by showing that TDO expression in human glioblastomas promotes tumor progression.

Toward Clinical Development of a TDO-inhibitor

The research team is moving forward to validate TDO inhibition in other preclinical models. Working closely with LICR colleagues in San Diego, the team will also conduct high-throughput screening to find a more stable TDO-inhibitor compound that can be advanced in clinical testing.

LICR plan
'/>"/>

Contact: Rachel Steinhardt
rsteinhardt@licr.org
212-450-1582
Ludwig Institute for Cancer Research
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Researchers Spot Potential Bile Duct Cancer Drug Targets
2. New therapeutic target to combat liver cancer discovered
3. Protein in the brain could be a key target in controlling Alzheimers
4. Rowley to receive Japan Prize for her role in the development of targeted cancer therapy
5. NIH grant targets inflammation in link between obesity and disease
6. U. of Nebraska to lead $25 million project targeting E. coli threat
7. Alcohol Targets Brain Reward Centers in Heavy Drinkers
8. Gene identified as a new target for treatment of aggressive childhood eye tumor
9. Unexpected discovery opens up new opportunities for targeting cancer
10. Researchers discover protein that may represent new target for treating type 1 diabetes
11. Targeted therapy extends progression-free survival of patients with advanced ovarian cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... PA (PRWEB) July 29, 2014 ... the Sewickley and Moon Township areas, has affiliated with ... Women’s Health will continue to deliver babies and perform ... need of advanced care will be referred to Allegheny ... are proud to be associated with West Penn Hospital ...
(Date:7/29/2014)... Representatives with BNatrl announced today that ... BNatrl Silver Solution 12ppm . , “It’s safe for ... BNatrl LLC. “It helps boost your immune system and ... and microbes.” , BNatrl develops and manufactures organic food ... 10 percent of profits being used to fund projects ...
(Date:7/29/2014)... 2014 Regents Health Resources, a consulting ... brought health care industry veteran Daryl Demonbreun and former ... lead the company’s ambitious plans to grow into a ... been moving along at a steady pace for nearly ... a notch,” says Bob Maier, founder and chief executive ...
(Date:7/29/2014)... According to the new market research report, "Fingerprint ... (Optical Prism, Pizeoelectric, Capacitive, and Adhesives), Application (Mobile ... & Finance), and Geography - Global Trends & ... the global Fingerprint Sensors Market is projected to ... high CAGR of 16.8% from 2014 to 2020. ...
(Date:7/29/2014)... This Latest Guidebook for Conducting Pharma ... Edition) not only provided a comprehensive and thorough knowledge ... imported drug registration but also introduced the practical operation ... you to use the Chinese trial venues to keep ... step by step. , The audiences of this guidebook ...
Breaking Medicine News(10 mins):Health News:Leading West Suburban OBGYN Practice, Premier Women’s Health, Joins Allegheny Health Network 2Health News:Leading West Suburban OBGYN Practice, Premier Women’s Health, Joins Allegheny Health Network 3Health News:BNatrl Launches New Silver Solution Product 2Health News:Sferrella and Demonbruen Join Regents Health Resources 2Health News:Fingerprint Sensors Market by Type (Swipe And Area) Estimated to Reach $14.35 Billion by 2020 - New Report by MarketsandMarkets 2Health News:Fingerprint Sensors Market by Type (Swipe And Area) Estimated to Reach $14.35 Billion by 2020 - New Report by MarketsandMarkets 3Health News:Fingerprint Sensors Market by Type (Swipe And Area) Estimated to Reach $14.35 Billion by 2020 - New Report by MarketsandMarkets 4Health News:Pharma Clinical Trials Market in China: Authorities for Drug New Study Now Available at MarketReportsOnline.com 2Health News:Pharma Clinical Trials Market in China: Authorities for Drug New Study Now Available at MarketReportsOnline.com 3Health News:Pharma Clinical Trials Market in China: Authorities for Drug New Study Now Available at MarketReportsOnline.com 4
... Reporter , WEDNESDAY, July 20 (HealthDay News) -- Some ... unexplained breathing problems that may be related to exposure ... disorders are emerging as a major consequence of service ... King, an assistant professor of pulmonary and critical care ...
... By Maureen Salamon HealthDay Reporter , ... both cause red, scaly skin rashes, but the similarities ... And now, examining patients suffering from both ... out the opposing immune system responses that prompt skin ...
... scientists have developed a gene-based test to distinguish harmless ... help some patients avoid needless surgery to remove the ... published in the July 20 issue of Science ... cysts are identified in more than a million patients ...
... July 20 (HealthDay News) -- The number of surgical errors ... study finds. In reviewing adverse events and close calls ... in the July 15 issue of the Archives of ... greater emphasis on safety, as well as improved training and ...
... Nev. Caffeine reduces muscle activity in the Fallopian tubes ... "Our experiments were conducted in mice, but this finding goes ... reduce a woman,s chance of becoming pregnant," says Sean Ward, ... Nevada School of Medicine, who conducted the study. ...
... The American Society for Radiation Oncology (ASTRO) has ... Junior Faculty Career Research Training Award and the ... Winners were selected by ASTRO,s Research Evaluation Committee. ... is awarded to stimulate interest in radiation research ...
Cached Medicine News:Health News:Breathing Problems Strike Soldiers Returning From Iraq 2Health News:Scientists Close in on Origins of Psoriasis, Eczema 2Health News:Scientists Close in on Origins of Psoriasis, Eczema 3Health News:Benign or cancerous? Gene test predicts cancer potential in pancreatic cysts 2Health News:Benign or cancerous? Gene test predicts cancer potential in pancreatic cysts 3Health News:Fewer Surgical Errors Reported at VA Medical Facilities 2Health News:Nevada School of Medicine researcher finds caffeine consumption, female infertility link 2
(Date:7/29/2014)... and TORONTO ... Acquisitions Corporation (OTCBB: ESAQ), an emerging pharmaceutical ... development of improved novel formulations and alternative ... announces expansion of its pharmaceutical development implementing ... direction includes large molecule drugs that will address ...
(Date:7/29/2014)... , July 29, 2014  Based on ... systems (PERS) market, Frost & Sullivan recognizes MobileHelp ... Award for Price Performance Value Leadership. MobileHelp,s leadership ... captures expectations for tech progression in personal emergency ... for these solutions. MobileHelp is at ...
(Date:7/29/2014)... Medical Corporation (Apex, TWSE: 4106), a leading player in the ... is appealing the judgment of the Regional Court of ... that found the headgear of certain mask models infringe a ... against various ResMed patents in major countries. Apex further reiterates ... ResMed filed the lawsuit with the Regional ...
Breaking Medicine Technology:EastGate Acquisitions Announces Expansion of its Pharmaceutical Developments Implementing its Sub-Micron Platform Technology 2EastGate Acquisitions Announces Expansion of its Pharmaceutical Developments Implementing its Sub-Micron Platform Technology 3EastGate Acquisitions Announces Expansion of its Pharmaceutical Developments Implementing its Sub-Micron Platform Technology 4Frost & Sullivan Applauds MobileHelp for its Targeted Supplies for the PERS Market 2Frost & Sullivan Applauds MobileHelp for its Targeted Supplies for the PERS Market 3Apex Continues Fighting Against Patents to Free Up Competition 2
... 2011 Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: ... and commercialization of products for central nervous system disorders, ... one of Israel,s leading private biotech, pharmaceutical and medical ... Israel. "We are excited to reach this ...
... Cell Therapeutics, Inc. ("CTI") (NASDAQ: CTIC ... that final results from the phase II OPAL study ... acute myeloid leukemia (AML) were presented by Jorge Cortes, ... Center during the Acute Myeloid Leukemia - Therapy, excluding ...
Cached Medicine Technology:Vanda Pharmaceuticals Enters into an Exclusive License Agreement with Megapharm Ltd. for Commercialization of Fanapt™ in Israel 2Vanda Pharmaceuticals Enters into an Exclusive License Agreement with Megapharm Ltd. for Commercialization of Fanapt™ in Israel 3Vanda Pharmaceuticals Enters into an Exclusive License Agreement with Megapharm Ltd. for Commercialization of Fanapt™ in Israel 4Final OPAL Phase II Results of Tosedostat Demonstrate Significant Response Rates in Elderly Patients with Treatment Refractory or Relapsed Primary or Secondary Acute Myeloid Leukemia (AML) 2Final OPAL Phase II Results of Tosedostat Demonstrate Significant Response Rates in Elderly Patients with Treatment Refractory or Relapsed Primary or Secondary Acute Myeloid Leukemia (AML) 3Final OPAL Phase II Results of Tosedostat Demonstrate Significant Response Rates in Elderly Patients with Treatment Refractory or Relapsed Primary or Secondary Acute Myeloid Leukemia (AML) 4
... and removal in the urinary tract. The nitinol ... shape following extreme torsion. The unique tipless design ... basket to open at the base of the ... reduces the likelihood of mucosal damage and perforation. ...
... Used for soft-tissue ... limited to paravaginal repairs, ... or rectocele. Surgisis® ES ... enhanced strength for intraoperative ...
... Used for temporary suprapubic urinary diversion ... puncture the bladder. The access sheath is ... Once the catheter is introduced, the access ... low-profile catheter support is included for external ...
... and a FAM-labeled probe targeting the VP1 gene ... ASR contains primers and a Texas Red-labeled probe ... an instrument that can detect FAM and Texas ... Analyte Specific Reagent* (ASR) program is comprised of ...
Medicine Products: